Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

May 2023

Secukinumab Improves Physical Function and Quality of Life and Inhibits Structural Damage in Patients with PsA with Sustained Remission or Low Disease Activity: Results From the 2-year Phase 3 FUTURE 5 Study

RMD Open 2023;9:e002939 doi 10.1136/rmdopen-2022-002939

Bao W,

Results from the 2-year phase 3 study FUTURE 5 show that the majority of patients with PsA who are treated with secukinumab were able to achieve sustained low disease activity or remission by week 104.

Keywords:

April 2023

Efficacy of Secukinumab on Dactylitis in Patients with Active Psoriatic Arthritis from the FUTURE 5 study

Clin Exp Rheumatol. 2023 doi: 10.55563/clinexprheumatol/vezf95

Kirkham B,

Nash P,

Reina D,

The presence of dactylitis was associated with a higher disease burden in patients with PsA compared with those without dactylitis at baseline. The aim of this study was to evaluate the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.